PTM BIO

Executive Summary

PTM BIO is a US-based biotechnology company founded in 2015 that specializes in the development and commercialization of proteomics tools and reagents, with a primary focus on post-translational modification (PTM) research. The company offers a comprehensive suite of services including proteomic analysis, bioinformatics, and custom antibody development, alongside a broad portfolio of research antibodies and IVD products. Its mission is to empower scientific discovery in epigenetics and proteomics. As a private, pre-clinical stage company, PTM BIO operates in the competitive proteomics market, serving academic and pharmaceutical researchers. The company's proprietary technologies enable the study of PTMs, which are critical for understanding diseases such as cancer, neurodegeneration, and metabolic disorders. Although specific financial details and pipeline candidates are not publicly available, PTM BIO's position in the growing proteomics field suggests potential for market adoption and strategic partnerships.

Upcoming Catalysts (preview)

• TBDLaunch of new IVD products or research-grade antibodies60% success